The global animal blood banking industry was valued at USD 1.2 billion in 2023 and is projected to grow at a CAGR of 14.5% through 2031, reaching USD 3.5 billion. This expansion is driven by:

• Rising complexity of surgeries (45% increase in transfusion-dependent procedures since 2020)
• Awareness of canine/feline blood types (80% of emergency clinics now test donors)
• Screening mandates for zoonotic diseases (FDA's 2024 guidelines on animal blood products)

Key Segments:

• Canine Blood Products (55% market share)
• Feline Blood Products (XX%)
• Equine/Livestock (XX%)

Growth Drivers

1. Trauma & Emergency Care Demand

• 1 in 5 ER cases now require transfusions (vs. 1 in 10 in 2018)
• Animal Blood Bank's mobile units serve 300+ hospitals nationwide

2. Specialty Medicine Advancements

• Canine DEA 1.1-negative universal donors cost $500 per unit.
• Fatal feline IMHA cases reduced by 60% with early transfusions.

3. Regulatory Standardization

• AAHA Blood Bank Accreditation launched 2023
• EU's Veterinary Blood Directive takes effect 2025

4. Novel Preservation Tech

• Cryopreserved platelets extend shelf life from 5 days to 2 years
• Lyophilized plasma enables rural emergency use

Regional Analysis

Case Study:

• BluePearl's National Blood Network reduced cross-match time from 4 hours to 30 minutes.

Competitive Landscape

Top 5 Players:

1. Animal Blood Bank International (35%) - 40+ canine/feline products
2. Hemopet (XX%) - DEA 1.1-negative greyhound donors
3. VetStem (XX%) - Stem cell+blood combo therapies
4. Midmark (XX%) - In-clinic blood processing systems
5. VetDC (XX%) - Canine lymphoma plasma trials

Recent Developments:

• FDA approval for first canine universal plasma (2024)
• Zoetis' USD 120M acquisition of Hemolife